Research Ongoing

Risk of Retinal Toxicity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Long-term Hydroxychloroquine Therapy

Scientific Study Title:

Risk of Retinal Toxicity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Long-term Hydroxychloroquine Therapy

Start Date:

2022

End Date:

2027

Research Category

# Arthritis Care, Treatments and Medications

Ready to Participate?

Life-changing arthritis research is only possible with your help!

Why do this research?

Reason For Research

Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are diseases of the immune system that affect many parts of the body (e.g., joints, heart, eyes, skin), and can result in other medical complications and death. A drug called hydroxychloroquine (HCQ) is commonly used to treat SLE and RA. Existing studies have highlighted benefits of HCQ, including less severe disease, fewer complications (e.g., blood clots, problems with pregnancy or kidneys), and longer life. Although HCQ is typically safe, inexpensive and easy to take, a serious long-term side-effect that may occur after years of taking HCQ is eye damage that could cause vision loss. Given the benefits and common use of HCQ, it is critical that the real risk of eye damage be determined and findings shared with doctors and patients so that patients receive the best and safest care.

Methodology

Execution of Research

Using administrative health data, we will identify all adults in BC with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) who have been taking hydroxychloroquine (HCQ) for at least 5 years. People who are interested in participating will have state-of-the-art eye testing done at a retinal specialist’s office, which is already the standard of care for people taking HCQ. This eye testing will take place once per year for 5 years. The goal of this study is to determine the risk of eye damage in people with SLE and RA, who are taking HCQ.

Who is involved?

Involvement

The research team consist of researchers, rheumatologists, retinal specialists (a type of ophthalmologist) and family physicians who are committed to delivering safe and appropriate care to the population.

Your participation in this study is voluntary and there are no foreseeable risks that are associated with this study. You will be asked to fill out a consent form before participating.

Your participation would involve signing a consent form and seeing a retinal specialist once per year for five years for eye exams. These exams are already the standard of care for people with systemic lupus erythematosus or rheumatoid arthritis who are taking hydroxychloroquine.

If you receive a letter of invitation in the mail, please consider participating in our study!

You may be eligible if you:

Are an adult (18 years and older)
Live with systemic lupus erythematosus or rheumatoid arthritis
Have been taking the medication hydroxychloroquine for 5 or more years
Live in British Columbia

Related Research

Are medications like Ozempic safe and effective for people with inflammatory arthritis and type 2 diabetes?

Using Artificial Intelligence to Streamline Research on Rheumatoid Arthritis Treatments

Evaluating a Decision Aid for Tapering Biologic Medications in Rheumatoid Arthritis

Improving quality of arthritis care for Indigenous populations

ChatRheum: Developing a Chatbot for Answering Rheumatology-Related Questions

What is the real risk of getting COVID-19, and how serious can it be, for British Columbians who are taking medications that affect their immune system?

2026 STUDIES TO WATCH

OUR RESEARCH

OUR PEOPLE

ARTHRITIS PATIENT ADVISORY BOARD

VOLUNTEER

PARTICIPATE IN RESEARCH